Patent 10828345

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (1)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2018-12-28 · recorded 2019-01-04 · reel 047568/0500 · ASSIGNMENT OF ASSIGNORS INTEREST

    YANCOPOULOS, GEORGE D.REGENERON PHARMACEUTICALS, INC.

    Correspondent: Patrick L. Premo · Regeneron Pharmaceuticals, Inc.

    inventor transfer

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

No unusual patterns detected regarding inventor departure.

Original assignee

The original assignee named on the issued patent US10828345B2 is Regeneron Pharmaceuticals Inc. They ship a product embodying the claims, specifically EYLEA™ (aflibercept), which was FDA-approved in November 2011 for the treatment of neovascular (wet) age-related macular degeneration, utilizing a dosing regimen similar to what is described in the patent. Regeneron Pharmaceuticals Inc. is a publicly traded biotechnology company focused on the development of medicines, and its current status is operating.

Assignment timeline

  • 2018-12-28 (executed) / recorded 2019-01-04 — Reel 047568/0500
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: YANCOPOULOS, GEORGE D.
    • Assignee: REGENERON PHARMACEUTICALS, INC.
    • Correspondent: PATRICK L. PREMO, ESQ.; Regeneron Pharmaceuticals, Inc.; 777 Old Saw Mill River Road; Tarrytown, NY 10591-6707.
    • Context: Internal transfer of patent rights from the inventor to the employing company.

The USPTO Patent Assignment Search results show only one recorded assignment for US10828345, which is the transfer from the inventor to the original assignee.

Timeline diagram

timeline
    title Ownership of US 10828345
    2018 : Filed by Regeneron
    2019 : Assigned by inventor to Regeneron
    2020 : Issued to Regeneron

NPE / troll-pattern signals

  1. Shell-entity transfer — Not present. The patent remains with Regeneron Pharmaceuticals Inc., an operating company. The only transfer is from the inventor to Regeneron.
  2. Known asserter in the chain — Not present. Regeneron Pharmaceuticals Inc. is a pharmaceutical operating company, not identified as a known NPE.
  3. Repeat correspondent across the chain — Unclear. There is only one recorded assignment in the chain from the inventor to Regeneron Pharmaceuticals Inc., with Patrick L. Premo, Esq. from Regeneron Pharmaceuticals, Inc. as the correspondent (Reel 047568/0500). Without multiple assignments, recurrence cannot be established.
  4. Cascading transfers — Not present. There is only one assignment recorded for this patent.
  5. Pre-litigation transfer — Not present. The assignment from the inventor to Regeneron Pharmaceuticals Inc. was executed on 2018-12-28 and recorded on 2019-01-04. Litigation activity related to the patent family is noted to have started in 2021 and 2023, significantly later than this internal transfer.
  6. Bankruptcy fire-sale — Not present. Regeneron Pharmaceuticals Inc. is an active, operating company.
  7. Privateering — Not present. The patent remains with the original operating company, Regeneron Pharmaceuticals Inc.
  8. Defensive aggregator (anti-NPE) — Not present. The patent is held by Regeneron Pharmaceuticals Inc., not a defensive aggregator.

Verdict

Insufficient data

There is only one recorded assignment for US patent 10828345 in the USPTO system, which is the standard transfer of ownership from the inventor to the original operating assignee, Regeneron Pharmaceuticals Inc., prior to the patent's issuance. This single, internal assignment provides insufficient data to identify any NPE/troll patterns. Regeneron Pharmaceuticals Inc. is a commercial entity known to produce products embodying the claims of the patent.

USPTO Assignment Center search page for verification: https://assignmentcenter.uspto.gov/

Generated 5/20/2026, 12:47:35 AM